Latest Breaking News On - Institute of nuclear medicine - Page 21 : vimarsana.com

DRDO's Antiviral Drug 2-DG Will Be Available Next Week

DRDO's Antiviral Drug 2-DG Will Be Available Next Week May 10, 2021, 11:05 IST The Defence Research and Development Organisation (DRDO) Chairman, Dr G Satheesh Reddy mentioned that the anti-Covid drug will be made available next week to those who are in need. He stated that the drug will provide relief to thousands of people who are struggling due to the infection. Satheesh Reddy said that over 10,000 sachets of the new anti-Covid drug- 2DG 2-deoxy-D-Glucose will be released on May 11 or 12. The  Drugs Controller General of India (DCGI) had approved the 2-DG drug developed by DRDO's Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad, for emergency use.

DCGI Approves Anti-COVID Drug Developed by DRDO for Emergency Use, How Will it Work?

DCGI Approves Anti-COVID Drug Developed by DRDO for Emergency Use, How Will it Work? A higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients and will be of immense benefit to the people suffering from COVID-19.   |  10 May 2021 7:14 AM GMT NEW DELHI: An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy's Laboratories (DRL), Hyderabad. Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. A higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients. The drug will be of immense benefit to the people suffering from COVID-19.

DCGI approves DRDO's anti-COVID drug for emergency use

Dr Reddy's Labs share rises over 4% post DCGI nod to anti-Covid drug

Dr Reddy's Labs share rises over 4% post DCGI nod to anti-Covid drug Dr Reddy's Laboratories stock touched an intraday high of Rs 5,422, rising 4.8% on BSE BusinessToday.In | May 10, 2021 | Updated 12:24 IST Dr Reddy’s Labs share opened with a gain of 3.02% at Rs 5,330 against previous close of Rs 5,173 on BSE. Dr Reddy's Laboratories share rose over 4% after Drugs Controller General of India (DCGI) approved the anti-COVID drug developed by DRDO (Defence Research and Development Organisation) in collaboration with the pharma firm for emergency use. Dr Reddy's Labs share opened with a gain of 3.02% at Rs 5,330 against previous close of Rs 5,173 on BSE.

Patanjali researchers were the first to published a study on 2-Deoxy-D-Glucose which is now approved by DCGI.

by Bhaswati Guha Majumder - May 10, 2021 05:28 AM Yoga guru Ramdev and Patanjali CEO Balkrishna Snapshot Researchers from Patanjali Research Institute, along with experts from Vivekanand Education Society’s Institute of Technology and Jain Vishva Bharati Institute, published their findings in 2020. With the country battling the second wave of coronavirus, the Drugs Controller General of India (DCGI) on 8 May approved a drug for emergency use. The drug is 2-deoxy-D-glucose (2-DG) which has been approved as an adjunct therapy in moderate-to-severe Covid-19 cases. "Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty," said the Defence Research and Development Organisation (DRDO).

India's DCGI allows use of oxygen dependence-lowering Covid-19 drug

Nifty, Sensex still rising – Monday closing report

Nifty, Sensex still rising – Monday closing report Moneylife Digital Team  0 We had mentioned in the previous week’s closing report that Nifty, Sensex may continue to rally. On Monday, the indices opened higher and made decent gains. On the NSE, there were 1,349 advances, 641 declines and 89 unchanged.   The trends of the major indices in the course of Monday’s trading are given in the table below:     Jindal Steel & Power made prepayment of Rs 2,462 crore to its term lenders as a strategy to reduce debt and build a robust balance sheet.   InterGlobe Aviation plans to explore all options to raise funds to increase its liquidity amid the aviation sector grappling with coronavirus pandemic woes. 

All you need to know about DRDO's new anti-COVID-19 drug 2-DG

All you need to know about DRDO's new anti-COVID-19 drug 2-DG The anti-Covid oral drug has been developed by the Defence Research and Development Organisation's (DRDO's) leading laboratory- Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr Reddy's Laboratories BusinessToday.In | May 10, 2021 | Updated 15:01 IST The 2-DG drug is expected to help hospitalised COVID-19 patients and reduce their supplemental oxygen dependence DRDO's new anti-Covid oral drug, 2-deoxy-D-glucose (2-DG), was recently granted emergency use approval by the Drug Controller General of India (DCGI) as an adjunct therapy in moderate cases of COVID-19.  The 2-DG drug is expected to help hospitalised COVID-19 patients and reduce their supplemental oxygen dependence.

Amid surge in cases, DRDO setting up two COVID care hospitals in Uttarakhand's Haldwani and Rishikesh

Amid rising cases of COVID-19, Defence Research and Development Organisation (DRDO) is building two COVID care hospitals in Haldwani and Rishikesh in Uttarakhand.

EXCLUSIVE: DRDO's anti-Covid oral drug to roll out by May 11

URL copied DRDO's anti-Covid oral drug to roll out by May 11 In an exclusive conversation with India TV, DRDO chief G. Satheesh Reddy on Sunday said the anti-COVID drug, which has been approved for emergency use, will be rolled out by May 11. Explaining further, the DRDO chief said the drug will help neutralise most of the COVID-19 symptoms and will prevent the growth of the virus inside the body. Regarding the availability of the drug, Reddy said arrangements for proper distribution across all hospitals need to be done and a team is already working on the same.  Speaking about the drug, the DRDO chief also said it would help improve the level of oxygen in the body. The drug is expected to help coronavirus patients within three days of consumption.